Merck revenue falls
October 28, 2014Manufacturing and Production, Sales and Marketing Frazier, Merck, Q3, Victrelis, hep C, sovaldi
Merck has posted a set of disappointing financials for the latest quarter as it cuts cost across its business to …
Karus Therapeutics appoints two heads
October 28, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Peter Finan, Simon Roitt, karus
UK drug development firm Karus Therapeutics has grown its R&D team via two new appointments in Dr Simon Roitt, who …
Celgene expands immunotherapy pipeline with Sutro
October 27, 2014Research and Development, Sales and Marketing Celgene, PD-1 and PD-L1, Q3, oncology, sutro
Celgene has extended its collaboration with Sutro Biopharma and added a buyout option for the firm as the two companies …
AZ oncology drug a ‘Phoenix from the flames’
October 27, 2014Sales and Marketing AstraZeneca, CHMP, EC, lynparza, olaparib, oncology
As the possibility of a deal with Pfizer fades, AstraZeneca is continuing its argument for independence as a key cancer …
Scenesse recommended for rare sun disease in Europe
October 27, 2014Sales and Marketing CHMP, Clinuvel Pharmaceuticals, EMA, EU, scenesse
The European Medicines Agency is recommending that Scenesse (afamelanotide) be approved for the prevention of severe sun burn in adults …
France Focus: Power without responsibility?
October 27, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing France, Lantus, Sanofi, Servier, hollande, perindopril, report
Population: 65.8 million (2013) Government: Unitary semi-presidential constitutional republic Leader: François Hollande of the centre-left Socialist Party Gross Domestic Product: …
Cubist Pharmaceuticals names chief executive
October 27, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing cubist, perez
US biopharma firm Cubist Pharmaceuticals has named Robert Perez as its chief executive and who will begin the role from …
Cancer drug discovery system ‘broken’
October 24, 2014Research and Development, Sales and Marketing Cancer, cancer research, oncology, paul workman
The global system for discovering new cancer drugs is ‘broken’ and failing to turn scientific advances into enough innovative new …
Lacklustre sales hit Lilly again
October 24, 2014Sales and Marketing Q3, cymbalta, humilin, lilly, sales, zyprexa
Lilly is enduring one of the bleakest financial years in its history as patent expiries continue to take chunks out …
Innovation director appointed to NHS England
October 24, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NHS England, tony young
NHS England has hired a new national clinical director for innovation in Professor Tony Young. Young’s role will be to …
UK government and partners pay £230m for disease research
October 23, 2014Research and Development, Sales and Marketing Arthritis Research UK, British Heart Foundation, Cancer Research UK, London, MRC, Osborne, UK, Wellcome Trust, dementia, research
A new partnership led by the Medical Research Council and the UK government will invest over £230 million in a …
GSK mulls $27 billion ViiV sell-off
October 23, 2014Medical Communications, Sales and Marketing AIDS, Advair, GSK, HIV, Pfizer, Q3, Shionogi, Tivicay, ViiV
After a difficult few years and another poor quarter, GlaxoSmithKline has announced that it is looking to float its fast-growing …
J&J appoints head of marketing in northern Europe
October 23, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Johnson and Johnson, yana Ignatova
Johnson & Johnson has appointed Yana Ignatova to the position of head of marketing for its northern Europe division. Reporting …
J&J announces ‘major commitment’ to Ebola effort
October 22, 2014Sales and Marketing Crucell, Ebola, J&J, JJ, Vaccine, bavarian, johnson, niaid
Johnson & Johnson will invest $200 million to accelerate and significantly expand the production of its Ebola vaccine programme. The …
Boehringer seeks more indications for IPF drug
October 22, 2014Research and Development, Sales and Marketing Boehringer, IPF, NSCLC, colectoral, crc, nintedanib, ofev
Boehringer Ingelheim’s nintedanib has entered Phase III studies for the treatment of colorectal cancer (CRC), which could add to the …
NICE under increased pressure over conflicts of interest
October 22, 2014Sales and Marketing GPs, NHS, NICE, UK, baker, conflict, mccoll, wollaston
A group of influential doctors is calling on the government to tighten up NICE’s conflicts of interests policy. In a …
Epic Sciences hires chief information officer
October 22, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Michael Giske, epic sciences
San Diego-based diagnostics development firm Epic Sciences has appointed Michael Giske as its chief information officer. Giske has more than …
Shire interim chief financial officer resigns
October 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Shire, james bowling, merger
Shire’s interim chief financial officer James Bowling has left the firm for water company Severn Trent following the collapse of …
Parkinson’s UK appoints research director
October 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Arthur Roach, Parkinson's UK
Charity organisation Parkinson’s UK has appointed a leading pharma industry expert in Dr Arthur Roach as its research director. Roach …
AbbVie ditches Shire as tax deal falters
October 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Obama, Shire, US government, tax, tax inversion
Tax rule changes coming from the US government have forced the collapse of a multi-billion dollar deal between Humira manufacturer …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
